'Drug Discovery Services Market will Reach $16.6 Billion in 2015' Predicts New Visiongain

LONDON, December 10, 2012 /PRNewswire/ --

A new report by visiongain predicts that the world market for drug discovery outsourcing will reach $16.6bn in 2015. That revenue forecast and others appear in Drug Discovery Outsourcing: World Market 2013-2023, published in November 2012. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the drug discovery outsourcing market will experience high revenue growth from 2013 to 2023. Expansion of the market will be stimulated by the rising costs of pharma research and development (R&D), advancing technologies and development of biologics (biological drugs). The complexity and technological advances in drug discovery will make it more challenging for many companies to conduct drug discovery in-house. Visiongain predicts that more companies will use contract service providers to gain access to technologies and skills not available in-company. Outsourcing has the advantage of flexibility, whereby a company does not have to invest heavily in facilities and equipment for research.

Opportunities in drug discovery include the formation of strategic alliances between pharmaceutical companies and contract research organisations (CROs) - a trend that will increase. In addition, niche CROs are well placed to provide services for companies needing specialised pharma research. In 2012, the drug discovery services industry is fragmented; that situation is unlikely to change soon. Service providers will still compete in crucial areas of price, quality and range of services, the study shows.

Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Drug discovery outsourcing is the reaction and solution to a changing pharma R&D climate. The global healthcare market will continue to have many unmet needs, requiring novel drugs to treat diseases. For example, targeted therapies in areas such as oncology and CNS disorders have high developmental needs. Outsourcing offers a platform for companies to reduce costs and improve their drug development, including getting faster and more-dependable results. There are also cost savings possible.

"Outsourcing drug discovery will result in strong revenue growth for those services in emerging countries such as China and India. Developed countries will also achieve high growth, especially to 2017, our findings show. However, entry into emerging national markets will involve challenges. For example, harmonisation of regulatory and intellectual property (IP) rights must be addressed to maintain confidence in developing countries' markets. Quality is paramount. The US and European early-stage drug development markets will also remain competitive, offering logistical advantages and well developed technologies, including biomarkers, genomics and proteomics."

Visiongain's report gives revenue forecasts to 2023 at overall world market, service submarket and national level. It forecasts world sales for the following segments:

• Chemical services

• Biological services

• Lead optimisation

• Lead identification and screening.

That investigation includes analyses of 13 leading companies, including Quintiles, Charles River Laboratories, Aptuit, Evotec, GenScript, PPD, WuXi AppTec and Albany Molecular Research.

The study includes researching trends and forecasting revenues in leading national markets. Countries analysed are the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC nations). The analysis also discusses opportunities and developments - technological and commercial.

Drug Discovery Outsourcing: World Market 2013-2023 adds to visiongain's range of analytical reports on industries and markets in healthcare, including those on pharmaceutical outsourcing.

For sample pages and further information concerning the Visiongain report Drug Discovery Outsourcing: World Market 2013-2023 please visit http://www.visiongain.com/Report/945/Drug-Discovery-Outsourcing-World-Market-2013-2023

Companies Listed

Abbott
AbCRO
Accugenix
Advion Bioanalytical Labs
Advion BioService
Albany Molecular Research, Inc (AMRI)
American Cancer Society
Andromeda Biotech
Apredica
Aptuit
Aptuit Laurus
Argenta
Ark Therapeutics
ArQule
Associação Brasileira de CROs (Abracro)
AstraZeneca
Bayer
Behrman Capital
Beijing Genomics Institute
BioDuro
BioDuro Biologics
BioFocus
BioPontis Alliance
Boehringer Ingelheim
Boston College
Bristol-Myers Squibb
Bundesverband Medizinischer Auftragsinstitute (BVMA)
Caprion Proteomics
Carlyle Group
Catalent Pharma Solutions
Cerebricon
Charles River Laboratories
CHDI Foundation
ChemBridge
ChemDiv
Compound Focus
Covance
CreaGen Biosciences
Crucell
Cyprotex
DeveloGen
Discovery Partners International
Domainex
Dow AgroSciences
Dow Chemical Company
Elan
Eli Lilly
Evotec
Evotec BioSystems AG
Excel PharmaStudies
Fidelity Growth Partners India (FGPI)
Food and Drug Administration (US FDA)
Furiex Pharmaceuticals
Galapagos
Genentech
GenScript
GlaxoSmithKline (GSK)
Glycoform
Great Lakes Chemical Corporation
Harvard Medical School
Hellman & Friedman
Horizon
Hypha Discovery
ICON
Inpharmatica
InSphero
InVentiv Health
Johnson & Johnson (J&J)
Janssen Pharmaceutica
Janssen Pharmaceutical Group
Kinaxo
Knopp Biosciences
Laurus Labs
Lonza
MAB Discovery
Massachusetts General Hospital
MedImmune
Merck & Co.
Microsoft
Midwest BioResearch
Millipore
National Institutes of Health (NIH)
Northeastern University
Novartis
Ono Pharmaceutical
Oxford Asymmetry International
Parexel
Peking Union Lawke Biomedical Development
Pfizer
Pharmaceutical Product Development (PPD)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharminox
Piedmont Research Center
PPD
PRA International
ProSkelia
ProStrakan
Proteome Sciences
Proteros Biostructutres GmbH (Proteros)
ProtonMedia
Quintiles
Roche
Rules-Based Medicine (RBM)
Samsung
Sanofi
Sareum
Servier
Shionogi
Sirius Analytical
Solvo Biotechnology
Southwestern Medical Center
Swiss Pharma Contract
Sygnature Discovery
SYN|thesis Med Chem
Taijitu Biologics
Takeda
Teva
The Dow Chemical Company
The European CRO Federation (EUCROF)
The Institute of Cancer Research
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
The Organization for Economic Cooperation and Development (OECD)
Tibotec
TRAC Microbiology
TransGenic
UCB
University of Manchester
VitualScopics
Wellcome Trust
WIL Research Laboratories
World Health Information Science Consultants (WHISCON)
World Health Organization (WHO)
World Trade Organization (WTO)
WuXi AppTec
WuXi PharmaTech

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)20-7336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Aviation, Automotive and Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44-(0)20-7336-6100